Glomerulonephritis, IGA clinical trials
The registry lists 253 studies for Glomerulonephritis, IGA across more than 10 countries. 98 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 84
- Recruiting
- 63
- Not yet recruiting
- 30
- Status unknown
- 26
- Active, not recruiting
- 20
- Terminated
- 17
Phase
- Phase 2
- 80
- Phase 3
- 50
- Phase 4
- 31
- Phase 1
- 18
- Early Phase 1
- 12
Where
- China
- 115
- United States
- 68
- United Kingdom
- 36
- Australia
- 34
- Spain
- 32
- France
- 30
Who runs them
Novartis Pharmaceuticals (17) · Otsuka Pharmaceutical Development & Commercialization, Inc. (6) · Guangdong Provincial People's Hospital (6) · Sun Yat-sen University (6) · Calliditas Therapeutics AB (5) · Centre Hospitalier Universitaire de Saint Etienne (5) · The Children's Hospital of Zhejiang University School of Medicine (5) · Chinese University of Hong Kong (4)
Studies
Recruiting first, then most recently updated. Showing 50 of 253 — search for more.
- A Study of JADE101 in Participants With Immunoglobulin A NephropathyRecruitingNCT07541287Phase 25 countries
- A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANNot yet recruitingNCT07773727Phase 21 country
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruitingNCT07498335Phase 36 countries
- Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)Not yet recruitingNCT07820995Phase 41 country
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)RecruitingNCT06935357Phase 328 countries
- To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic StrategiesRecruitingNCT07822100Not applicable1 country
- IgA Nephropathy Registration Initiative of High Quality (INSIGHT)RecruitingNCT030019471 country
- Correlation of Microbiome and Metabonomics With IgA NephropathyRecruitingNCT051908481 country
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney DiseasesNot yet recruitingNCT07389499Early Phase 11 country
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANRecruitingNCT06994845Phase 38 countries
- A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A NephropathyNot yet recruitingNCT07807995Phase 3
- Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseRecruitingNCT06989359Phase 28 countries
- Chinese Adults With Kidney DiseaseRecruitingNCT07522099Phase 21 country
- Efficacy and Safety of Nefecon on Prevention of Relapse of IgA NephropathyRecruitingNCT07604311Phase 41 country
- Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA NephropathyNot yet recruitingNCT07785128Phase 21 country
- The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)RecruitingNCT048587241 country
- Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)Not yet recruitingNCT07770815Phase 3
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.RecruitingNCT06858319Phase 39 countries
- Universal STAR-T Cell Injection in Autoimmune Kidney DiseasesNot yet recruitingNCT07746453Not applicable1 country
- A Study to Assess the Effects of Zigakibart on IgA Nephropathy.RecruitingNCT07146906Phase 211 countries
- The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.Enrolling by invitationNCT07750249Early Phase 11 country
- Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular DiseasesRecruitingNCT07614477Phase 21 country
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GRecruitingNCT06419205Phase 22 countries
- Study of WAL0921 in Patients With Glomerular Kidney DiseasesRecruitingNCT06466135Phase 27 countries
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.RecruitingNCT07203404Early Phase 11 country
- Study of Ravulizumab in Pediatric Participants With Primary IgANRecruitingNCT07024563Phase 37 countries
- Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgANRecruitingNCT06797518Phase 25 countries
- Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)Not yet recruitingNCT07730632Phase 21 country
- A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA NephropathyRecruitingNCT07582133Phase 21 country
- Epithelial Dysmetabolism and Renal Fibrosis in ANCA VasculitisRecruitingNCT070102501 country
- RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune DiseasesNot yet recruitingNCT07674147Early Phase 11 country
- Atacicept in Multiple Glomerular DiseasesRecruitingNCT06983028Phase 21 country
- RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)RecruitingNCT069262441 country
- Study of BHV-1400 in IgA NephropathyRecruitingNCT07054684Phase 12 countries
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptEnrolling by invitationNCT06674577Phase 21 country
- Mediators of Loin Pain in IgA NephropathyNot yet recruitingNCT076495381 country
- A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA NephropathyNot yet recruitingNCT07642050Phase 3
- Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN StudyRecruitingNCT06350630Phase 21 country
- A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A NephropathyRecruitingNCT04663204Phase 21 country
- A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyRecruitingNCT07616700Phase 21 country
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingNCT07390123Phase 31 country
- CD19/BCMA UCAR-T for B Cell-Related Autoimmune DiseaseRecruitingNCT07586267Early Phase 11 country
- Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.RecruitingNCT075859811 country
- A Study of SHR-2173 in Participants With Primary IgA NephropathyRecruitingNCT07354932Phase 21 country
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesRecruitingNCT05003986Phase 28 countries
- A Study of YKST02 in Participants With Primary IgA NephropathyRecruitingNCT07498673Early Phase 11 country
- Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)Enrolling by invitationNCT05248659Phase 2/331 countries
- Clinical Experience With Sparsentan in Switzerland in IgA NephropathyNot yet recruitingNCT075553011 country
- SLN12140 in Adult Participants With IgA Nephropathy in ChinaNot yet recruitingNCT07553494Phase 21 country
- Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune NephropathyNot yet recruitingNCT07535138Early Phase 11 country